Cantor Fitzgerald reissued their buy rating on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a report released on Tuesday morning. The brokerage currently has a $17.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also commented on CRBP. JMP Securities raised their price objective on Corbus Pharmaceuticals Holdings from $9.00 to $20.00 and gave the company an outperform rating in a research report on Tuesday. Aegis reissued a buy rating on shares of Corbus Pharmaceuticals Holdings in a research report on Monday. Finally, Noble Financial reissued a buy rating and set a $19.00 price objective on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, November 11th.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 3.988% during midday trading on Tuesday, reaching $7.825. 771,335 shares of the company’s stock traded hands. The stock’s market cap is $342.33 million. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $4.45. Corbus Pharmaceuticals Holdings has a one year low of $1.01 and a one year high of $10.78.

In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran acquired 17,900 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, August 26th. The stock was bought at an average cost of $3.92 per share, for a total transaction of $70,168.00. Following the acquisition, the chief financial officer now owns 299,310 shares of the company’s stock, valued at $1,173,295.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sean F. Moran acquired 30,800 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Thursday, September 8th. The stock was acquired at an average price of $5.12 per share, with a total value of $157,696.00. Following the completion of the acquisition, the chief financial officer now directly owns 330,110 shares in the company, valued at approximately $1,690,163.20. The disclosure for this purchase can be found here. 11.60% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the company. Knoll Capital Management LP acquired a new stake in Corbus Pharmaceuticals Holdings during the third quarter valued at approximately $16,717,000. Fosun International Ltd acquired a new stake in Corbus Pharmaceuticals Holdings during the third quarter valued at approximately $4,753,000. Morgan Stanley increased its stake in Corbus Pharmaceuticals Holdings by 12.4% in the third quarter. Morgan Stanley now owns 29,909 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,300 shares during the last quarter. Northern Trust Corp increased its stake in Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 13,222 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Corbus Pharmaceuticals Holdings by 14.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 216,139 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 27,000 shares during the last quarter. Institutional investors own 25.39% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.